Table 1.
Baseline patient characteristics in the experimental and validation cohorts.
| Experimental Cohort | Validation Cohort | P value | |
|---|---|---|---|
| Age, n (%) | |||
| >60 years | 15 (18.3) | 6 (17.6) | 0.934 |
| ≤60 years | 67 (81.7) | 28 (82.4) | |
| Sex, n (%) | |||
| Male | 78 (95.1) | 33 (97.1) | 0.640 |
| Female | 4 (4.9) | 1 (2.9) | |
| Clinical T stage, n (%) | |||
| T1-T3 | 30 (36.6) | 15 (44.1) | 0.449 |
| T4 | 52 (63.4) | 19 (55.9) | |
| Clinical N stage, n (%) | |||
| N0 | 13 (15.9) | 9 (26.5) | 0.184 |
| N1-N3 | 69 (84.1) | 25 (73.5) | |
| Clinical TNM stage, n (%) | |||
| Stage I-III | 13 (15.9) | 9 (26.5) | 0.184 |
| Stage IV | 69 (84.1) | 25 (73.5) | |
| Histologic grade, n (%) | |||
| Grade 1–2 | 77 (93.9) | 29 (85.3) | 0.133 |
| Grade 3 | 5 (6.1) | 5 (14.7) | |
| Tumor volume, mean ± SD, | 36.67 ± 30.66 | 34.7 ± 39.2 | 0.778 |
| Follow-up time, mean ± SD, , month | 39.34 ± 34.65 | 49.45 ± 36.84 | 0.163 |
| Institution, n (%) | |||
| Institution 1 | 65 (79.3) | 25 (73.5) | 0.500 |
| Institution 2 | 17 (20.7) | 9 (26.5) | |
Abbreviations: n, number; T, tumor; N, lymph node, SD, standard deviation.